So far, the technology has been tested in monkeys, and the results of those experiments appeared Jan. 22 in Science Translational Medicine.
“We’re the first to show a nerve guide without any cells was able to bridge a large, two-inch gap between the nerve stump and its target muscle,” said senior author Kacey Marra, professor of plastic surgery at Pitt and core faculty at the McGowan Institute for Regenerative Medicine. “Our guide was comparable to, and in some ways better than, a nerve graft.”
According to a U.S. Army Institute of Surgical Research study, half of wounded American soldiers return home with injuries to their arms and legs. The injuries often result in damaged nerves and disability, according to research published in The Bone & Joint Journal. Among civilians, car crashes, machinery accidents, cancer treatment, diabetes and even birth trauma can cause significant nerve damage, affecting more than 20 million Americans altogether, the National Institute of Neurological Disorders and Strokes reported.
Peripheral nerves can regrow up to a third of an inch on their own, but if the damaged section is longer than that, the nerve can’t find its target. Often, the disoriented nerve gets knotted into a painful ball called a neuroma.
The most common treatment for longer segments of nerve damage is to remove a skinny sensory nerve at the back of the leg—which causes numbness in the leg and other complications, but has the least chance of being missed by the injured person—chop it into thirds, bundle the pieces together and then sew them to the end of the damaged motor nerve, usually in the arm. But only about 40 to 60% of the motor function typically returns.
“It’s like you’re replacing a piece of linguine with a bundle of angel hair pasta,” Marra said. “It just doesn’t work as well.”
Marra’s nerve guide returned about 80% of fine motor control in the thumbs of four monkeys, each with a two-inch nerve gap in the forearm.
The guide is made of the same material as dissolvable sutures and peppered with a growth-promoting protein—the same one delivered to the brain in a recent Parkinson’s trial, results of which were published in the journal Brain—which releases slowly over the course of months.
The experiment had two controls: an empty polymer tube and a nerve graft. Since monkeys’ legs are relatively short, the usual clinical procedure of removing and dicing a leg nerve wouldn’t work. So, the scientists removed a two-inch segment of nerve from the forearm, flipped it around and sewed it into place, replacing metaphorical linguine with linguine, and setting a high bar for the nerve guide to match.
Functional recovery was just as good with Marra’s guide as it was with this best-case-scenario graft, and the guide outperformed the graft when it came to restoring nerve conduction and replenishing Schwann cells—the insulating layer around nerves that boosts electrical signals and supports regeneration. In both scenarios, it took a year for the nerve to regrow. The empty guide performed significantly worse all around.
With these promising results in monkeys, Marra wants to bring her nerve guide to human patients. She’s working with the Food and Drug Administration (FDA) on a first-in-human clinical trial and spinning out a startup company, AxoMax Technologies Inc.
“There are no hollow tubes on the market that are approved by the FDA for nerve gaps greater than an inch. Once you get past that, no off-the-shelf tube has been shown to work,” Marra said. “That’s what’s amazing here.”
Additional authors on the study include Neil Fadia; Jacqueline Bliley; Gabriella DiBernardo; Donald Crammond, PhD; Benjamin Schilling; Wesley Sivak, MD, PhD; Alexander Spiess, MD; Kia Washington, MD; Matthias Waldner, MD; Liao Han Tsung, PhD; Isaac James, MD; Danielle Minteer, PhD; Casey Tompkins-Rhoades; Deok-Yeol Kim; Riccardo Schweizer, MD; Debra Bourne, MD; Adam Cottrill, George Panagis, Asher Schusterman, MD; Francesco Egro, MD; Insiyah Campwala; Tyler Simpson, MS; Douglas Weber, PhD; Trent Gause, MD; Jack Brooker; Tvisha Josyula; Astrid Guevara; Alexander Repko and Christopher Mahoney, all of Pitt.
This study was funded by the Armed Forces Institute of Regenerative Medicine (award number W81XWH-14-2-0003). MedGenesis Therapeutix Inc., supplied the growth-promoting protein. Axomax Technologies was formed after the experiments were completed.
